Table 1 Main characteristics of patients with major outcomes at the 6-month follow-up after COVID-19 recovery.
From: Long-term follow-up of recovered MPN patients with COVID-19
THROMBOSIS (N = 5) | Fatal event | MPN | Age | COVID-19 acute phase disposition | Cytoreduction | Anticoagulation |
|---|---|---|---|---|---|---|
Intestinal ischemia | Yes | MF | 71.7 | Regular ward | No | No |
Splenic infarction | No | MF | 72.3 | Regular ward | Ruxolitinib | No |
DVT (legs) + PE | No | ET | 61.5 | Regular ward | Ruxolitinib | No |
Acute myocardial infarction | No | PV | 80.6 | Regular ward | Hydroxyurea | No |
Pheripheral arterial thrombosis | No | MF | 75.4 | Regular ward | Ruxolitinib | Yes |
MALIGNANCY (N = 5) | Fatal event | MPN | Age | COVID-19 acute phase disposition | Cytoreduction | MPN disease duration |
|---|---|---|---|---|---|---|
AML | Yes | MF | 49.3 | ICU | Hydroxyurea | 5.9 years |
AML | No | ET | 78.3 | Regular ward | Hydroxyurea | 6.0 years |
AML | No | Pre-PMF | 82.1 | Regular ward | Hydroxyurea | 3.8 years |
Non-Hodgkin lymphoma | No | ET | 60.0 | Regular ward | Hydroxyurea | 8.6 years |
Progression of Parotid Carcinoma | Yes | MF | 77.3 | Regular ward | Ruxolitinib | 21.7 years |
DEATH CAUSES (N = 8) | Fatal event | MPN | Age | COVID-19 acute phase disposition | Cytoreduction | MPN disease duration |
|---|---|---|---|---|---|---|
AML | – | MF | 49.3 | ICU | Hydroxyurea | 5.9 years |
Progression of solid cancer (parotid) | – | MF | 77.3 | Regular ward | Ruxolitinib | 21.7 years |
Suspected lung cancer | – | MF | 80.9 | Regular ward | unk | 10.9 years |
Multi Organ Failure | – | ET | 85.7 | Regular ward | Hydroxyurea | 5.8 years |
Thrombosis | – | MF | 71.7 | Regular ward | No | 10.2 years |
Heart failure | – | MF | 82.4 | Home | Unknown | 24.7 years |
Heart failure | – | Pre-PMF | 88.7 | Home | No | 8.8 years |
Unknown | – | ET | 87.0 | Regular ward | Unknown | 0.8 years |
